A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms of the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract infecti...
A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms for the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV))-associated lower respiratory tract infec...
Scully, M;
Rayment, R;
Clark, A;
Westwood, J. P;
Cranfield, T;
Gooding, R;
Bagot, C. N;
Taylor, A;
Sankar, V;
Gale, D;
Dutt, T;
McIntyre, J;
Lester, W.
The objective of this guideline is to provide healthcare professionals with clear, up-to-date and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) and related thrombotic microangiopathies (TMAs), including complement-mediated haemolytic uraemic syndrome (CM HUS); these ar...
Thrombotic Microangiopathies/diagnosis,
Purpura, Thrombotic Thrombocytopenic/diagnosis,
Antibodies, Monoclonal/therapeutic use,
Immunization, Passive,
Blood-Derivative Drugs,
Thrombotic Microangiopathies/therapy,
Purpura, Thrombotic Thrombocytopenic/therapy
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults....
People with relapsed or refractory diffuse large B-cell lymphoma who cannot have an
autologous stem cell transplant usually have polatuzumab vedotin plus rituximab and
bendamustine.
The clinical evidence is from a small study that did not directly compare tafasitamab plus
lenalidomide with any other trea...
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Commercial arrangement
There is a simple discount patient access scheme for eptinezumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact United...
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Commercial arrangement
There is a managed access agreement, which includes a patient access scheme, for trastuzumab derux...
Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.
Commercial arrangements
There is a simple discount patient access scheme for lenvatinib and a commercial access agreement for pembrolizumab. NHS organisations can g...
Barbosa, Alexandre Naime;
Chebabo, Alberto;
Pérez, Clevy;
Cunha, Clóvis Arns;
Luna, David de;
Nunes, Estevão Portela;
Zambrano, Gabriela;
Ferreira, Juliana Carvalho;
Croda, Júlio;
Falavigna, Maicon;
Silva, Monica Maria Gomes da;
Cimerman, Sergio;
Parahiba, Suena Medeiros;
Tanni, Suzana;
Bernardo, Wanderley Marques;
Rodriguez-Morales, Alfonso J.
Since the beginning of the COVID-19 pandemic, therapeutic options for treating COVID-19 have been investigated at different stages of clinical manifestations. Considering the particular impact of COVID-19 in the Americas, this document aims to present recommendations for the pharmacological treatment of ...
The presented clinical guideline is focused primarily on the treatment of COVID-19. It also deals with medicinal products that are not recommended for use, organ support, specifics of treatment in children and adolescents, multisystem inflammatory syndrome in children and adolescents (MIS-C, PIMS-TS), pr...
